STOK: stoketherapeutics.com Price to Earnings Adjusted for Growth Rate
Stoke Therapeutics (STOK) currently relies on external financing due to a lack of stable earnings. The P/E to growth trend captures this status, where 0.00 determines the current level of this parameter. TANGO patents for epilepsy treatment support growth, although complex cryo-logistic drug delivery chains are increasing costs.
Analytical breakdowns for Stoke Therapeutics (STOK)
- stock value and consensus price forecast:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Stoke Therapeutics|STOK - Long-Term Debt to Capital|Current Liabilities to Capital stoketherapeutics.com|STOK - Company Debts|Debt to Net Assets Ratio Stoke|STOK - Company Long-Term Debts|Company Short-Term Debts Stoke Therapeutics|Critical Liquidity Ratio stoketherapeutics.com
- earnings and valuation multiples information:
STOK - Net Profit|Expected Net Profit Stoke Therapeutics|STOK - Price to Earnings Ratio|Forward P/E Multiple Stoke Corp|STOK - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Stoke|STOK - Operating profit EBITDA|Net earnings per share for the last four quarters Stoke Therapeutics|STOK - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months stoketherapeutics.com|STOK - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Stoke Therapeutics
Fundamental company analysis:Stoke Therapeutics Inc, STOK
This metric compares the current P/E ratio with earnings growth rates, allowing for the determination of an asset's fair value based on its dynamics. An analysis of the PEG ratio helps identify the hidden potential of Stoke Therapeutics (STOK), whose unique RNA therapy, upon approval, will create a monopoly ecosystem in the treatment of orphan epilepsy with the highest possible level of patient retention.
Competing companies
PEG Multiple Tempus AI, Inc (TEM)|PEG Multiple QGEN (Qiagen Group)|Isis Pharmaceuticals (IONS) - Price to Earnings Adjusted for Growth Rate|RGEN: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio RNA (aviditybiosciences.com)|CRSP (CRISPR Therapeutics) - Price/Earnings to Growth Multiple|WGS: Company Value to Earnings Growth Ratio|RARE (Ultragenyx Pharma) - PEG Multiple|BEAM: Growth-Adjusted Payback Ratio|PEG Multiple SRPT|TWST - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio 10x Genomics TXG|Growth-Adjusted Payback Ratio NTLA|BioLife Corp - PEG Multiple|WVE - PEG Multiple|Maze Therapeutics Inc (MAZE) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio SION (sionnatx.com)|PRME (Prime Medicine) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Taysha Gene Therapies Inc TSHA|Price/Earnings to Growth Multiple QURE (uniQure Corp)|PEG Multiple MeiraGTx Corp (MGTX)|REGENXBIO Inc. - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio SLDB (solidbio.com)|Ocugen - PEG Multiple|Growth-Adjusted Market Cap to Net Income Pacific Biosciences of California, Inc. PACB|BNTC: PEG Multiple|Price/Earnings to Growth Multiple Design Corp|Price/Earnings to Growth Ratio Rocket Pharmaceuticals|4dmoleculartherapeutics.com (FDMT) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Lexeo Therapeutics (LXEO)|Growth-Adjusted Market Cap to Net Income korrobio.com|Editas - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio SLN (Silence Therapeutics Corp)|PRQR - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Codexis, Inc.|Sangamo Therapeutics, Inc. (SGMO) - Price/Earnings to Growth Ratio|Nautilus Bio (NAUT) - PEG Multiple|MGX (Metagenomi, Inc) - PEG Multiple|Growth-Adjusted P/E Ratio DTIL (Precision BioSciences Inc.)|Price/Earnings to Growth Ratio Generation Bio Co. (GBIO)|boundlessbio.com - Growth-Adjusted P/E Ratio|PEG Multiple XCUR (Exicure)|PEG Multiple Imunon Inc IMNN|PHIO - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Mustang Bio, Inc. MBIO|RNAZ (transcodetherapeutics.com) - Price/Earnings to Growth Multiple|BNGO: Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Applied DNA Sciences, Inc.|Price to Earnings Adjusted for Growth Rate bluebird bio Inc. BLUE|Price/Earnings to Growth Ratio ImmunoPrecise Antibodies (IPA)|PEG Multiple Omega Therapeutics Corp (OMGA)|PEG Multiple OMIC (Singular Genomics Systems)|regulusrx.com (RGLS) - Price to Earnings Adjusted for Growth Rate|SYRS: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio TBIO (Telesis Bio Inc.)|TCON (TRACON) - Price/Earnings to Growth Multiple|UBX: Company Value to Earnings Growth Ratio
